Prior MMR or Tdap vaccination may reduce risk of severe COVID-19

Researchers in the United States have shown that prior Measles-Mumps-Rubella (MMR) or Tetanus-Diphtheria-pertussis (Tdap) vaccination may reduce the risk of severe outcomes in patients with coronavirus disease 2019 (COVID-19).

The team provided evidence that infection with the COVID-19 causative agent – severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – reactivates memory T cells previously generated by MMR and Tdap vaccination and that this may reduce the severity of COVID-19.

"Our findings provide definitive cellular and molecular evidence that heterologous adaptive immunity exists between SARS-CoV-2 and antigens present in Tdap and MMR vaccines," say the researchers from  Brigham and Women's Hospital & Harvard Medical School in Boston, Massachusetts, the University of California Davis, and the Cleveland Clinic in Ohio.

"Heterologous adaptive immunity" refers to an immune response to one pathogen that is mediated by the memory T cells previously generated against a different pathogen, either through infection or vaccination.

"Heterologous immunity can variously alter disease outcomes by providing enhanced immunity or by exacerbating immunopathology or lessening viral control," says Tanya Mayadas and colleagues.

In an extensive analysis of more than 73,000 COVID-19 patients, the team found that severe disease outcomes were reduced among individuals previously vaccinated against MMR or Tdap.

The researchers say the findings may have implications for the development of vaccines against future novel pathogens since a vaccine's efficacy may correlate with its ability to harness pre-existing memory T cells generated by prior infection or vaccination.

A pre-print version of the research paper is available on the bioRxiv* server, while the article undergoes peer review.

T cells are critical to controlling viral infection

T cells are critical in the early control of acute viral infection and for stimulating B cells to produce protective antibodies against viral antigens.

The expansion of T cells following productive immunity typically generates a memory T cell population that can persist for decades and rapidly respond to reinfection.

A major goal in vaccine development is, therefore, the induction of strong and durable T-cell memory.

Studies of SARS-CoV-2-specific T-cell responses have suggested that key viral targets include the spike protein (that mediates the initial stage of host cell infection), the nucleocapsid protein (that packages viral RNA into new virions) and the envelope protein (needed for replication).

Interestingly, several studies have shown that memory T cells that are specific to coronaviruses related to SARS-CoV-2 – including those that cause the common cold – cross-react with SARS-CoV-2 antigens.

"Moreover, profiling of the TCR [T cell receptor] repertoire of T cells isolated from unexposed and SARS-CoV-2 convalescent patients and expanded in vitro with predicted immunodominant viral peptides show clonal expansion of T cells with TCR sequences recognizing peptides from other viruses including human cytomegalovirus and influenza A," says Mayadas and colleagues.

However, "the impact of these pre-existing, cross-reactive memory T cells on disease outcomes are largely unknown," writes the team.

What did the researchers do?

The researchers used an assay for antigen-specific T cell responses to determine whether SARS-CoV-2 protein-specific T cells from convalescent individuals or recipients of COVID-19 vaccines cross-reacted with antigens present in MMR and Tdap vaccines.

The MMR and Tdap vaccines are known to be highly effective at eliciting long-lasting protective immunity and therefore T and B cell memory responses, explains the team.

T cell responses to SARS-CoV-2, MMR and Tdap antigens in SARS-CoV-2 infected and uninfected donors
T cell responses to SARS-CoV-2, MMR and Tdap antigens in SARS-CoV-2 infected and uninfected donors. A) Blood was collected from uninfected (UNI) and PCR-confirmed, SARS-CoV-2 Infected (INF) donors. Plasma was analyzed for antibodies to SARS-CoV-2 antigens and cytokines. Blood was divided and treated with Isotype control or AAC for 2hrs and neutrophils were then isolated and cultured in GM-CSF for 2 days. AAC treated neutrophils converted to APCs (nAPC) while Isotype treated controls remained neutrophils. PBMC were harvested to isolate CD3+ T cells and monocytes, which were cultured in cytokines to generate dendritic cells (moDC). Neutrophils (Isotype), nAPC (AAC) and moDC were loaded with antigens and cocultured with autologous T cells on IFN-g ELISpot plates for 18hrs. B) nAPC from unexposed (1-4) and exposed (1-9) were co-cultured with autologous CD3 T cells and Spike-S1 on IFNg-ELISpot plates. The number of spots per 1 X 106 cells is reported. C) IgG titers in sera of unexposed and exposed donors to indicated SARS-CoV-2 antigens. Red arrows in B)-C) identify samples with high frequency of IFN-g+ T cells but no detectable SARS-CoV-2 antibodies. D) nAPCs generated from 8 unexposed and 18 exposed donors were loaded with indicated individual SARS-CoV-2, MMR and Tdap antigens and analyzed for T cell responses as in A) (left panel). Representative images of wells with IFN-g+ spots from an ELISpot assay are shown (right panel). *p<0.05; **p<0.005 by two-tailed Mann-Whitney test with Bonferroni correction for multiple comparisons. E) A correlation of Spike-S1 or Nucleocapsid derived IFN-g+ spots with indicated vaccine antigens (circles) and percent of nAPCs generated (diamonds) in exposed donors was conducted using Spearman’s rank correlation coefficients (r). *p<0.05; **p<0.005 using two-way analysis of variance and Bonferroni’s multiple comparison test. F) Cytokine levels detected in the supernatants of neutrophils treated with isotype or AAC (nAPC) and monocyte derived dendritic cells (moDC) cultured for 72hrs. **p<0.005 using two-way analysis of variance and Bonferroni’s multiple comparison test. G) As in B), ELISpot assays measuring IFN-g secretion by T cells co-cultured with nAPCs pulsed with combined SARS-CoV-2 (Spike S1, Nucleocapsid, RBD), MMR (Measles, Mumps and Rubella) or Tdap (Tetanus, Diphtheria and Pertussis) antigens were evaluated in the presence of two independent anti-IL15 antibodies (top panel), anti- IL-1b/anti-IL18 or anti-TNFa (bottom panel). The number of spots per 106 T cells was quantified for each antigen combination. Two-way analysis of variance and Dunnett’s multiple comparison test was used. **p<0.005. All Data expressed are mean ± sem.

The researchers identified a strong correlation between responses to the SARS-CoV-2 spike and nucleocapsid proteins and responses to MMR and Tdap vaccine proteins in both convalescent individuals and those who had been immunized with COVID-19 vaccines.

The researchers say the findings suggest that the MMR and Tdap reactive memory T cells will enhance immunity to the SARS-CoV-2 spike variants that may emerge as population immunity continues to expand.

"In uninfected individuals immunized with the SARS-CoV-2 vaccine, the markedly enhanced T cell responses to MMR and Tdap antigens compared to the same evaluated prior to vaccination suggests that protective heterologous T cell immunity in vaccinated individuals may be induced by MMR and Tdap vaccine antigens," they write.

Could MMR or Tdap vaccination alleviate severe disease in COVID-19 patients?

Next, the team conducted a propensity-weighted analysis of 73,582 COVID-19 patients adjusted for multiple patient characteristics to determine whether disease severity was attenuated in individuals with prior MMR or Tdap vaccination.

This revealed that severe outcomes (hospitalization, transfer to intensive care or death) were reduced in MMR- and Tdap- vaccinated individuals by 38-32% and 23-20%, respectively.

What are the implications for vaccine development?

"Our studies provide evidence of broad cross-reactivity between T cells responsive to SARS-CoV-2, MMR and Tdap antigens in humans," writes Beck and colleagues.

The researchers say the prevalence of heterologous immunity observed here may have implications for vaccine development against future novel pathogens:

"We posit that intentional MMR or Tdap vaccine-induced heterologous immunity to SARS-CoV-2 could enhance the effectiveness of SARS-CoV-2 vaccines by generating an expanded population of SARS-CoV-2-specific memory T cells (and, in turn, B cells) that respond vigorously to the vaccines and, in countries where SARS-CoV-2 vaccines are not yet available, provide protection from severe disease."

*Important Notice

bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Journal reference:
Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2021, May 05). Prior MMR or Tdap vaccination may reduce risk of severe COVID-19. News-Medical. Retrieved on October 06, 2022 from

  • MLA

    Robertson, Sally. "Prior MMR or Tdap vaccination may reduce risk of severe COVID-19". News-Medical. 06 October 2022. <>.

  • Chicago

    Robertson, Sally. "Prior MMR or Tdap vaccination may reduce risk of severe COVID-19". News-Medical. (accessed October 06, 2022).

  • Harvard

    Robertson, Sally. 2021. Prior MMR or Tdap vaccination may reduce risk of severe COVID-19. News-Medical, viewed 06 October 2022,


  1. Jeff Kleinman Jeff Kleinman United States says:

    I heard about the MMR-covid relationship way back in July 2020 and so I got my adult MMR booster shot in August 2020, and then again got my second adult MMR booster shot in December 2020, before the covid vaccines became available to me.  I then got my first and second Pfizer shots in April 2021.  As far as I know, they are protecting me.  I assume that because I got the MMR shots long before my covid shots, I should have had a robust immune response to the covid vaccine.  I hope so.  If they offer a covid booster shot, I plan to get one.  I think we will need one before this coming winter with the variants mutating so much.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Common germline variants of APOE contribute to differential COVID-19 outcomes